Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy

Proteomics - Clinical Applications

Volumn 5, Issue 11-12, 2011, Pages 644-649

  Stelzhammer, Viktoria ^a   Rothermundt, Matthias ^b   Guest, Paul C ^a   Michael, Nikolaus ^b   Sondermann, Carina ^b   Kluge, Wolfgang ^a   Martins de Souza, Daniel ^a   Rahmoune, Hassan ^a   Bahn, Sabine ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anaesthesia; ECT; Multiplexed serum profiling

Indexed keywords

FATTY ACID BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 7; METHOHEXITAL; MUSCLE RELAXANT AGENT; PROLACTIN; PROTEIN S100B; SUXAMETHONIUM; TUMOR NECROSIS FACTOR ALPHA;

ANESTHESIA; ANESTHESIA MECHANISM; ARTICLE; ELECTROCONVULSIVE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR DEPRESSION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; THERAPY EFFECT;

ANESTHESIA; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; METHOHEXITAL; MIDDLE AGED; NEUROMUSCULAR DEPOLARIZING AGENTS; PROTEOMICS; SUCCINYLCHOLINE;

EID: 84855179752     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100040     Document Type: Article

References (48)

1. Mathew, S. J., Electroconvulsive therapy in treatment - resistant depression. Primary Psychiatry 2005, 12, 52-56.
2. Clothier, J. L., Freeman, T., Snow, L., Medical student attitudes and knowledge about ECT. J. ECT 2001, 17, 99-101.
3. Petrides, G., Fink, M., Husain, M. M., Knapp, R. G. et al., ECT remission rates in psychotic versus nonpsychotic depressed patients: A report from CORE. J. ECT 2001, 17, 244-253.
4. Sackeim, H. A., Prudic, J., Devanand, D. P., Kiersky, J. E. et al., Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N. Engl. J. Med. 1993, 328, 839-846.
5. UK ECT Review Groups, Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet 2003, 361, 799-808.
6. de Jonghe, F., Kool, S., van Aalst, G., Dekker, J., Peen, J., Combining psychotherapy and antidepressants in the treatment of depression. J. Affect. Disord. 2001, 64, 217-229.
7. Khan, A., Mirolo, M. H., Hughes, D., Bierut, L., Electroconvulsive therapy. Psychiatr. Clin. North Am. 1993, 16, 497-513.
8. Ding, Z. and White, P. F., Anesthesia for electroconvulsive therapy. Anesth. Analg. 2002, 94, 1351-1364.
9. Devanand, D. P., Dwork, A. J., Hutchinson, E. R., Bolwig, T. G., Sackeim, H.A., Does ECT alter brain structure? Am. J. Psychiatry 1994, 151, 957-970.
10. Bertenshaw, G. P., Yip, P., Seshaiah, P., Zhao, J. et al., Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 2872-2881.
11. Benjamini, Y. and Hochberg, Y., Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B - Methodol. 1995, 57, 289-300.
12. Team, R. D. C., R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2009, Vienna, Austria.
13. Pelsers, M. M., Hanhoff, T., Van der Voort, D., Arts, B. et al., Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin. Chem. 2004, 50, 1568-1575.
14. Berrios, G. E., Bulbena, A., Martinez, A. R., Ortega Gazo, D. et al., Significant rise in plasma insulin after electroconvulsive therapy. Acta Psychiatr. Scand. 1986, 74, 222-224.
15. Williams, K., Smith, J., Glue, P., Nutt, D., The effects of electroconvulsive therapy on plasma insulin and glucose in depression. Br. J. Psychiatry 1992, 161, 94-98.
16. Lehtimaki, K., Keranen, T., Huuhka, M., Palmio, J. et al., Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. J. ECT 2008, 24, 88-91.
17. Fluitman, S. B., Heijnen, C. J., Denys, D. A., Nolen, W. A. et al., Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J. Affect. Disord. 2011, 131, 388-392.
18. Abrams, R. and Swartz, C. M., Electroconvulsive therapy and prolactin release: relation to treatment response in melancholia. Convuls. Ther. 1985, 1, 38-42.
19. Aperia, B., Thoren, M., Wetterberg, L., Prolactin and thyrotropin in serum during electroconvulsive therapy in patients with major depressive illness. Acta Psychiatr. Scand. 1985, 72, 302-308.
20. Balldin, J., Factors influencing prolactin release induced by electroconvulsive therapy. Acta Psychiatr. Scand. 1982, 65, 365-369.
21. Deakin, J. F., Ferrier, I. N., Crow, T. J., Johnstone, E.C., and Lawler, P., Effects of ECT on pituitary hormone release: relationship to seizure, clinical variables and outcome. Br. J. Psychiatry 1983, 143, 618-624.
22. Giltay, E. J., Kho, K. H., and Blansjaar, B. A., Serum markers of brain-cell damage and C-reactive protein are unaffected by electroconvulsive therapy. World J. Biol. Psychiatry 2008, 9, 231-235.
23. Lisanby, S. H., Devanand, D. P., Prudic, J., Pierson, D. et al., Prolactin response to electroconvulsive therapy: Effects of electrode placement and stimulus dosage. Biol. Psychiatry 1998, 43, 146-155.
24. Ohman, R., Walinder, J., Balldin, J., Wallin, L., Prolactin response to electroconvulsive therapy. Lancet 1976, 2, 936-937.
25. Swartz, C., Abrams, R., Prolactin levels after bilateral and unilateral ECT. Br. J. Psychiatry 1984, 144, 643-645.
26. Wahlund, B., von Rosen, D., ECT of major depressed patients in relation to biological and clinical variables: A brief overview. Neuropsychopharmacology 2003, 28, S21-26.
27. Whalley, L. J., Rosie, R., Dick, H., Levy, G. et al., Immediate increases in plasma prolactin and neurophysin but not other hormones after electroconvulsive therapy. Lancet 1982, 2, 1064-1068.
28. Agelink, M. W., Andrich, J., Postert, T., Wurzinger, U. et al., Relation between electroconvulsive therapy, cognitive side effects, neuron specific enolase, and protein S-100. J. Neurol. Neurosurg. Psychiatry 2001, 71, 394-396.
29. Zachrisson, O. C., Balldin, J., Ekman, R., Naesh, O. et al., No evident neuronal damage after electroconvulsive therapy. Psychiatry Res. 2000, 96, 157-165.
30. Arts, B., Peters, M., Ponds, R., Honig, A. et al., S100 and impact of ECT on depression and cognition. J. ECT 2006, 22, 206-212.
31. Hestad, K. A., Tonseth, S., Stoen, C. D., Ueland, T., and Aukrust, P., Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 2003, 19, 183-188.
32. Altar, C. A., Laeng, P., Jurata, L. W., Brockman, J. A. et al., Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J. Neurosci. 2004, 24, 2667-2677.
33. Newton, S. S., Collier, E. F., Bennett, A. H., Russell, D. S., Duman, R. S., Regulation of growth factor receptor bound 2 by electroconvulsive seizure. Brain Res. Mol. Brain Res. 2004, 129, 185-188.
34. Newton, S. S., Collier, E. F., Hunsberger, J., Adams, D. et al., Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J. Neurosci. 2003, 23, 10841-10851.
35. Nibuya, M., Morinobu, S., Duman, R. S., Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995, 15, 7539-7547.
36. Laborde, E., Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ. 2010 [Epub ahead of print], 17, 1373-1380.
37. Zourek, M., Kyselova, P., Mudra, J., Krcma, M. et al., The relationship between glycemia, insulin and oxidative stress in hereditary hypertriglyceridemic rat. Physiol. Res. 2008, 57, 531-538.
38. Yamac, H., Bultmann, I., Sliwa, K., Hilfiker-Kleiner, D., Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart 2010, 96, 1352-1357.
39. Sanchez Palacios, A., Ortiz Ponce, M., Rodriguez Perez, A., Schamann Medina, F., Garcia Marrero, J. A., Modification of mediators of immune reaction after general anaesthesia. Allergol. Immunopathol. (Madrid) 2004, 32, 352-360.
40. Luef, G., Hormonal alterations following seizures. Epilepsy. Behav. 2010, 19, 131-133.
41. Linstedt, U., Meyer, O., Kropp, P., Berkau, A. et al., Serum concentration of S-100 protein in assessment of cognitive dysfunction after general anesthesia in different types of surgery. Acta Anaesthesiol. Scand. 2002, 46, 384-389.
42. Giraudet, A., Hinchcliff, K. W., Kohn, C. W., McKeever, K. H., Early insulin response to an intravenous glucose tolerance test in horses. Am. J. Vet. Res. 1994, 55, 379-381.
43. McNair, P. D., Colman, P. G., Alford, F. P., Harrison, L. C., Reproducibility of the first-phase insulin response to intravenous glucose is not improved by retrograde cannulation and arterialization or the use of a lower glucose dose. Diabetes Care 1995, 18, 1168-1173.
44. Toft, A. D., Falahati, A., Steensberg, A., Source and kinetics of interleukin-6 in humans during exercise demonstrated by a minimally invasive model. Eur. J. Appl. Physiol. 2011, 111, 1351-1359.
45. Oriente, A., Hundley, T., Hubbard, W. C., MacGlashan, D. W., Jr., Preliminary characterization of diacylglycerol generation in human basophils: temporal relationship to histamine release and resolution of degranulation. J. Leukoc. Biol. 1997, 61, 637-642.
46. Castell, J. V., Geiger, T., Gross, V., Andus, T. et al., Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem. 1988, 177, 357-361.
47. Lotze, M. T., Frana, L. W., Sharrow, S. O., Robb, R. J., Rosenberg, S. A., In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 1985, 134, 157-166.
48. Zahn, G., Greischel, A., Pharmacokinetics of tumor necrosis factor alpha after intravenous administration in rats. Dose dependence and influence of tumor necrosis factor beta. Arzneimittelforschung 1989, 39, 1180-1182.